Madrigal Pharmaceuticals’ Rezdiffra: A Promising First-Mover in MASH Treatment with Strong Growth Potential

Analyst Jay Olson of Oppenheimer maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), retaining the price target of $475.00.

Jay Olson has given his Buy rating due to a combination of factors that highlight Madrigal Pharmaceuticals’ promising position in the market. The company’s drug, Rezdiffra, is seen as a pioneering treatment for MASH, with potential commercial coverage expected to advance significantly. This optimism is bolstered by the drug’s penetration among high-prescribing physicians and the potential for further growth in the F4c opportunity, supported by updated clinical data.
Rezdiffra’s performance is expected to remain strong, with significant script volume growth anticipated. The drug benefits from a first-mover advantage, and the recent EASL guidelines recommending Rezdiffra as a first-line treatment for non-cirrhotic MASH could drive further uptake. Additionally, the ongoing outcomes trials for Rezdiffra could expand its commercial potential, particularly in NASH cirrhosis, supporting Olson’s positive outlook and the Buy rating.

According to TipRanks, Olson is a 3-star analyst with an average return of 0.4% and a 31.69% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Biogen, and Gilead Sciences.

In another report released on April 24, Evercore ISI also maintained a Buy rating on the stock with a $392.00 price target.